Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-12-18
2007-12-18
McGarry, Sean (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S024500
Reexamination Certificate
active
10703783
ABSTRACT:
The present invention provides a pharmaceutical composition for the prevention or treatment of angiostenosis, comprising a compound inhibiting the function of midkine (MK) in blood vessel tissues as an effective ingredient. The present invention is useful for the prevention or treatment of angiostenosis attributed to arteriosclerosis or restenosis after percutaneous transluminal coronary angioplasty (PTCA). As compounds inhibiting the function of MK, antisense oligonucleotides that bind to a segment of a single-stranded mRNA transcribed from the MK gene to inhibit the synthesis of MK protein in cells, antibodies against the MK protein, and such can be used.
REFERENCES:
patent: 5629284 (1997-05-01), Unoki et al.
patent: 5670477 (1997-09-01), Poduslo et al.
patent: 5733871 (1998-03-01), Alps et al.
patent: 6083907 (2000-07-01), Uchida et al.
patent: 2003/0072739 (2003-04-01), Takada et al.
patent: 2004/0219129 (2004-11-01), Yoshida et al.
patent: PCT/US95/08781 (1996-02-01), None
Green et al. Antisense Oligonucleotides: An Evolving Technology for the Modulation of Gene Expression in Human Disease. Antisense Therapy in Human Disease (2000) vol. 191: pp. 93-105. Elsevier Science Inc.
Jen et al. Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies. Stem Cells (2000) vol. 18: pp. 307-319. AlphaMed Press.
Branch et al. A Good Antisense Molecule is Hard to Find. TIBS (1998) vol. 23, pp. 45-50. Elsevier Science LTD.
Carmeliet et al. Mouse models of angiogenesis, arterial stenosis, atherosclerosis and hemostatis. Cardiovascular Research (1998), vol. 39: 8-33. Elsevier.
Hayashi et al. Antisense oligoribonucleotide as to the growth factor midkine suppresses neointima formation induced by balloon injury. Am. J. Physiol. Heart Circ. Physiol. 2005, vol. 288: H2203-H2209. American Physiological Society.
Bennet et al. Antisense Therapy for Angioplasty Restenosis. Circulation 1995, vol. 92: 1981-1993. American Heart Association, Inc.
Garas et al. Overview of therapies for prevention of restenosis after coronary interventions. Pharmacology & Therapeutics 2001, vol. 92: 165-178. Elsevier Science Inc.
Morishita et al. Intimal Hyperplasia after Vascular Injury is Inhibited by Antisense cdk 2 Kinase Oligonucleotides. J. Clin. Invest. 1994, vol. 93: 1458-1464.
Horiba et al. Midkine (MK) plays a crucial role in neointimal formation. J. American College of Cardiology, Feb. 1991, vol. 33, No. 2 SUPPL. A: 229A-230A.
Rha, S.Y. et al. “Comparison of Biological Phenotypes According to Midkine Expression in Gastric Cancer Cells and Their Autocrine Activities Could be Modulated by Pentosan Polysulfate”Cancer Letters, 1997, pp. 37-46, vol. 118.
Yoshida, Y. et al. “Midkine is present in the early stage of cerebral infarct”,Dev. Brain Res., 1995, 85:25-30.
Gewirtz, A.M. et al. “Facilitating oligonucleotide delivery: helping antisense deliver on its promise”Proc. Natl. Acad. Sci.1996, vol. 93, pp. 3161-3163.
Agrawal, S. (1996)Trends Biotechnol. vol. 14, No. 10, pp. 376-387.
Berk, Bradford C. et al. (May 1991) “Pharmacologic Roles of Heparin and Glucocorticoids to Prevent Restenosis After Coronary Angioplasty”J. Am. Coll Cardiol. 17(6 Suppl B):111B-117B.
Braasch, D.A. (2002)Biochemistry, vol. 41, No. 14, pp. 4503-4510.
Branch, A.D. (1998)Trends Biochem. Sci. vol. 23, No. 2, pp. 45-50.
Gewirtz, et al.Proc. Natl. Acad. Sci. vol. 93, pp. 3161-3163, no date.
Griffith, M. (1997) “Midkine and Secondary Neurulation”Teratology. vol. 55, pp. 213-223.
Ohyama, Y. et al. (1994) “Isolation and identification of midkine and pleiotrophin in bovine follicular fluid”Mol. Cell Biol.vol. 105, pp. 203-208.
Sun, Xue-Zhi et al. (Dec. 1997) “An Immunohistochemical Study of Radial Glial Cells in the Mouse Brain Prenatally Exposed to γ-irradiation”Journal of Neuropathology and Experimental Neurology. vol. 56, No. 12, pp. 1339-1348.
Tamm, I. et al. (2001)The Lancet.vol. 358, pp. 489-497.
Wang, Sha-Yan et al. (1998) “Midkine exists in astrocytes in the early stage of cerebral infarction”Developmental Brain Researchvol. 106, pp. 205-209.
Horiba Mitsuru
Ikematsu Shinya
Kadomatsu Kenji
Muramatsu Takashi
Sakuma Sadatoshi
Chong Kimberly
McGarry Sean
Saliwanchik Lloyd & Saliwanchik
Takashi Muramatsu
LandOfFree
Pharmaceutical compositions for the prevention and treatment... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical compositions for the prevention and treatment..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions for the prevention and treatment... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3835737